vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and GEN Restaurant Group, Inc. (GENK). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $49.7M, roughly 1.7× GEN Restaurant Group, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -3.8%, a 10.7% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -9.0%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-5.6M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Gen Korean BBQ is an American chain of all-you-can-eat Korean barbecue restaurants mainly concentrated around the Western U.S. It opened in 2011, and has since grown to 43 locations as of 2024.
BLLN vs GENK — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $49.7M |
| Net Profit | $5.7M | $-1.9M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | -24.5% |
| Net Margin | 6.8% | -3.8% |
| Revenue YoY | 117.4% | -9.0% |
| Net Profit YoY | 138.3% | -821.4% |
| EPS (diluted) | $0.10 | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $49.7M | ||
| Q3 25 | $83.5M | $50.4M | ||
| Q2 25 | — | $55.0M | ||
| Q1 25 | — | $57.3M | ||
| Q4 24 | — | $54.7M | ||
| Q3 24 | $38.4M | $49.1M | ||
| Q2 24 | — | $53.9M | ||
| Q1 24 | — | $50.8M |
| Q4 25 | — | $-1.9M | ||
| Q3 25 | $5.7M | $-566.0K | ||
| Q2 25 | — | $-261.0K | ||
| Q1 25 | — | $-301.0K | ||
| Q4 24 | — | $-206.0K | ||
| Q3 24 | $-14.9M | $25.0K | ||
| Q2 24 | — | $277.0K | ||
| Q1 24 | — | $496.0K |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -24.5% | ||
| Q3 25 | 11.5% | -7.4% | ||
| Q2 25 | — | -3.4% | ||
| Q1 25 | — | -3.8% | ||
| Q4 24 | — | -2.4% | ||
| Q3 24 | -32.9% | 0.2% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | -3.8% | ||
| Q3 25 | 6.8% | -1.1% | ||
| Q2 25 | — | -0.5% | ||
| Q1 25 | — | -0.5% | ||
| Q4 24 | — | -0.4% | ||
| Q3 24 | -38.8% | 0.1% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | $-0.37 | ||
| Q3 25 | $0.10 | $-0.11 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-0.06 | ||
| Q4 24 | — | $-0.05 | ||
| Q3 24 | $-1.47 | $0.01 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $2.8M |
| Total DebtLower is stronger | $55.0M | $13.6M |
| Stockholders' EquityBook value | $-239.5M | $26.5M |
| Total Assets | $327.5M | $259.9M |
| Debt / EquityLower = less leverage | — | 0.51× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.8M | ||
| Q3 25 | $195.2M | $4.8M | ||
| Q2 25 | — | $9.6M | ||
| Q1 25 | — | $15.4M | ||
| Q4 24 | — | $23.7M | ||
| Q3 24 | — | $22.1M | ||
| Q2 24 | — | $29.2M | ||
| Q1 24 | — | $28.1M |
| Q4 25 | — | $13.6M | ||
| Q3 25 | $55.0M | $10.8M | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $6.5M | ||
| Q4 24 | — | $6.9M | ||
| Q3 24 | — | $7.2M | ||
| Q2 24 | — | $7.6M | ||
| Q1 24 | — | $7.7M |
| Q4 25 | — | $26.5M | ||
| Q3 25 | $-239.5M | $38.1M | ||
| Q2 25 | — | $41.0M | ||
| Q1 25 | — | $42.8M | ||
| Q4 24 | — | $44.1M | ||
| Q3 24 | $-242.9M | $46.5M | ||
| Q2 24 | — | $45.9M | ||
| Q1 24 | — | $40.4M |
| Q4 25 | — | $259.9M | ||
| Q3 25 | $327.5M | $245.5M | ||
| Q2 25 | — | $246.3M | ||
| Q1 25 | — | $232.4M | ||
| Q4 24 | — | $240.4M | ||
| Q3 24 | — | $225.7M | ||
| Q2 24 | — | $218.8M | ||
| Q1 24 | — | $214.5M |
| Q4 25 | — | 0.51× | ||
| Q3 25 | — | 0.28× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.17× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-426.0K |
| Free Cash FlowOCF − Capex | $6.5M | $-5.6M |
| FCF MarginFCF / Revenue | 7.7% | -11.3% |
| Capex IntensityCapex / Revenue | 8.8% | 10.5% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-24.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-426.0K | ||
| Q3 25 | $13.8M | $-1.6M | ||
| Q2 25 | — | $3.3M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | — | $1.4M | ||
| Q2 24 | — | $5.6M | ||
| Q1 24 | — | $3.5M |
| Q4 25 | — | $-5.6M | ||
| Q3 25 | $6.5M | $-7.7M | ||
| Q2 25 | — | $-6.3M | ||
| Q1 25 | — | $-4.7M | ||
| Q4 24 | — | $165.0K | ||
| Q3 24 | — | $-6.8M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-586.0K |
| Q4 25 | — | -11.3% | ||
| Q3 25 | 7.7% | -15.3% | ||
| Q2 25 | — | -11.5% | ||
| Q1 25 | — | -8.2% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | -13.9% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | -1.2% |
| Q4 25 | — | 10.5% | ||
| Q3 25 | 8.8% | 12.0% | ||
| Q2 25 | — | 17.5% | ||
| Q1 25 | — | 11.9% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | — | 16.9% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 57.96× | ||
| Q2 24 | — | 20.06× | ||
| Q1 24 | — | 7.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
GENK
Segment breakdown not available.
